EMA Backs Enhertu Plus Pertuzumab as Potential New First-Line Standard for HER2-Positive Metastatic Breast Cancer

As reported on PharmaBiz, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation supporting approval of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate…

Continue Reading EMA Backs Enhertu Plus Pertuzumab as Potential New First-Line Standard for HER2-Positive Metastatic Breast Cancer
Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers
source: shutterstock.com

Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers

Carisma Therapeutics, the manufacturer of CT-0508, issued a press release stating that researchers are conducting a combination study using CAR-M cell therapy plus Keytruda (pembrolizumab) in the treatment of overexpressing…

Continue Reading Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers